Elanco Animal HealthELAN
ELAN
About: Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
Employees: 9,800
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
514% more call options, than puts
Call options by funds: $67.9M | Put options by funds: $11M
133% more funds holding in top 10
Funds holding in top 10: 3 [Q2] → 7 (+4) [Q3]
31% more repeat investments, than reductions
Existing positions increased: 157 | Existing positions reduced: 120
0% more capital invested
Capital invested by funds: $7.01B [Q2] → $7.02B (+$13M) [Q3]
1.58% less ownership
Funds ownership: 98.34% [Q2] → 96.76% (-1.58%) [Q3]
4% less funds holding
Funds holding: 398 [Q2] → 383 (-15) [Q3]
22% less first-time investments, than exits
New positions opened: 52 | Existing positions closed: 67
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$14
18%
upside
Avg. target
$17.33
46%
upside
High target
$20
68%
upside
3 analyst ratings
2 positive
67%
1 neutral
33%
0 negative
0%
UBS Andrea Alfonso 0% 1-year accuracy 0 / 1 met price target | 52%upside $18 | Buy Initiated | 9 Dec 2024 |
Leerink Partners Daniel Clark 0% 1-year accuracy 0 / 2 met price target | 18%upside $14 | Market Perform Initiated | 2 Dec 2024 |
Barclays Balaji Prasad 48% 1-year accuracy 21 / 44 met price target | 68%upside $20 | Overweight Maintained | 8 Nov 2024 |
Financial journalist opinion
Based on 148 articles about ELAN published over the past 30 days
Neutral
Accesswire
2 days ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Elanco Animal Health Incorporated (ELAN) And Encourages Stockholders to Reach Out
NEW YORK CITY, NY / ACCESSWIRE / December 22, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN.
Neutral
PRNewsWire
5 days ago
Elanco to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
GREENFIELD, Ind. , Dec. 19, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 43rd Annual J.P.
Neutral
Accesswire
6 days ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Elanco Animal Health Incorporated (ELAN) And Encourages Stockholders to Connect
NEW YORK CITY, NY / ACCESSWIRE / December 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN.
Neutral
PRNewsWire
2 weeks ago
NYSE: ELAN Lawsuit Alert: Investors who lost money with Elanco Animal Health Incorporated shares should contact the Shareholders Foundation
SAN DIEGO , Dec. 9, 2024 /PRNewswire/ -- The Shareholders Foundation, Inc. announces that a lawsuit is currently pending for certain investors in shares of Elanco Animal Health Incorporated (NYSE: ELAN). Long-Term investors who purchased shares of Elanco Animal Health Incorporated (NYSE: ELAN) prior to November 2023 and continue to hold any of those NYSE: ELAN shares also have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Neutral
Accesswire
2 weeks ago
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Elanco Animal Health Incorporated of Class Action Lawsuit and Upcoming Deadlines - ELAN
NEW YORK, NY / ACCESSWIRE / December 7, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Elanco Animal Health Incorporated ("Elanco" or the "Company") (NYSE:ELAN) and certain officers. The class action, filed in the United States District Court for the District Of Maryland, and docketed under 24-cv-02912 is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Elanco securities between November 7, 2023 and June 26, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
Neutral
Accesswire
2 weeks ago
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of December 6, 2024 in Elanco Lawsuit - ELAN
NEW YORK, NY / ACCESSWIRE / December 6, 2024 / If you suffered a loss on your Elanco Animal Health Incorporated (NYSE:ELAN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/elanco-animal-health-incorporated-lawsuit-submission-form?prid=115246&wire=1 or contact Joseph E. Levi, Esq.
Neutral
GlobeNewsWire
2 weeks ago
ELAN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Elanco Animal Health Incorporated Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Elanco Animal Health Incorporated (“Elanco” or “the Company”) (NYSE: ELAN) and certain of its officers.
Neutral
Accesswire
2 weeks ago
Lost Money on Elanco Animal Health Incorporated (ELAN)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / December 6, 2024 / If you suffered a loss on your Elanco Animal Health Incorporated (NYSE:ELAN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/elanco-animal-health-incorporated-lawsuit-submission-form?prid=115199&wire=1 or contact Joseph E. Levi, Esq.
Neutral
Business Wire
2 weeks ago
ELAN Deadline Today: Rosen Law Firm Urges Elanco Animal Health Incorporated (NYSE: ELAN) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of all purchasers of securities of Elanco Animal Health Incorporated (NYSE: ELAN) between November 7, 2023 and June 26, 2024, both dates inclusive (the “Class Period”). Elanco is an “animal health company that develops, manufactures, and markets products for pets and farm animals.” For more information, submit a form, email attorney Phillip Kim, or give us a.
Neutral
Accesswire
2 weeks ago
Elanco (ELAN) Investors Alerted to Today's Lead Plaintiff Deadline in Securities Class Action - Hagens Berman
SAN FRANCISCO, CA / ACCESSWIRE / December 6, 2024 / Animal health company Elanco (ELAN) and its most senior executives are the targets of a securities class action suit, alleging that they downplayed potential safety concerns related to Elanco's new oral Janus kinase inhibitor, Zenrelia, while overstating its prospects for a rapid U.S. market entry. Hagens Berman urges Elanco Animal Health Incorporated (NYSE:ELAN) investors who suffered substantial losses to submit your losses now.
Charts implemented using Lightweight Charts™